NASDAQ$ELVN
Enliven Therapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ending June 30, 2021, and reviewed recent business highlights.
Imara Inc. reported its second-quarter financial results, highlighting accelerated enrollment in Phase 2b trials for sickle cell disease and beta-thalassemia. The company also presented positive IMR-687 data and is developing a Phase 2 proof-of-concept study for HFpEF. A $50 million follow-on offering extends their cash runway through 2022.
- Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021.
- Positive IMR-687 data in sickle cell disease presented at the European Hematology Association (EHA) Annual Congress.
- HFpEF Phase 2 proof-of-concept study under development; FDA interaction planned in fourth quarter of 2021.
- Closed $50 million July follow-on offering extends cash runway through 2022.
Headline financials
Revenue & EPS history
Enliven Therapeutics · Revenue · Quarterly
$0
Forward guidance
Imara provided financial guidance for the full year 2021 and expects its current cash resources to fund operations through the end of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-0.4%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+7.4%
Avg return
30 days after
48%
11 / 23 earnings
Positive
+17.6%
Q2 2020
Best reaction
-22.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +4.3% | +3.4% | +35.1% | |
| Q3 2025 | -0.3% | +11.3% | -16.9% | |
| Q2 2025 | -0.8% | -1.1% | -0.1% | |
| Q1 2025 | +0.4% | +19.7% | +29.3% | |
| Q4 2024 | -3.5% | -7.7% | -14.6% | |
| Q3 2024 | -8.3% | -8.4% | -14.8% | |
| Q1 2024 | -2.0% | -5.9% | -10.1% | |
| Q4 2023 | -2.4% | +43.0% | +71.8% | |
| Q3 2023 | -9.3% | -12.4% | -4.5% | |
| Q2 2023 | -2.0% | -8.0% | -7.1% | |
| Q1 2023 | -2.4% | -0.3% | +8.8% | |
| Q4 2022 | +2.1% | +4.5% | +2.6% | |
| Q3 2022 | +0.4% | -5.5% | -1.3% | |
| Q2 2022 | +2.5% | -1.7% | -3.4% | |
| Q1 2022 | -6.1% | -11.5% | -12.2% | |
| Q4 2021 | +11.1% | +22.2% | -27.8% | |
| Q3 2021 | +0.8% | -3.8% | -20.2% | |
| Q2 2021 | +0.3% | -18.0% | -14.5% | |
| Q1 2021 | +12.8% | +15.8% | +27.3% | |
| Q4 2020 | -22.5% | -19.5% | -31.7% | |
| Q3 2020 | -3.4% | +13.9% | +57.0% | |
| Q2 2020 | +17.6% | +19.8% | +8.1% | |
| Q1 2020 | +1.1% | +4.4% | +108.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro